Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

Cinedigm (CIDM) Competitors

Cinedigm logo

CIDM vs. BTX, ALFIW, and NLOK

Should you be buying Cinedigm stock or one of its competitors? The main competitors of Cinedigm include Brooklyn ImmunoTherapeutics (BTX), Alfi (ALFIW), and NortonLifeLock (NLOK). These companies are all part of the "information" sector.

Cinedigm vs.

Cinedigm (NASDAQ:CIDM) and Brooklyn ImmunoTherapeutics (NYSE:BTX) are both small-cap information companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, community ranking, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

In the previous week, Cinedigm had 1 more articles in the media than Brooklyn ImmunoTherapeutics. MarketBeat recorded 1 mentions for Cinedigm and 0 mentions for Brooklyn ImmunoTherapeutics. Cinedigm's average media sentiment score of 0.00 equaled Brooklyn ImmunoTherapeutics'average media sentiment score.

Company Overall Sentiment
Cinedigm Neutral
Brooklyn ImmunoTherapeutics Neutral

8.0% of Cinedigm shares are owned by institutional investors. Comparatively, 26.0% of Brooklyn ImmunoTherapeutics shares are owned by institutional investors. 16.4% of Cinedigm shares are owned by insiders. Comparatively, 20.5% of Brooklyn ImmunoTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
CinedigmN/A N/A N/A
Brooklyn ImmunoTherapeutics N/A N/A N/A

Brooklyn ImmunoTherapeutics has lower revenue, but higher earnings than Cinedigm. Cinedigm is trading at a lower price-to-earnings ratio than Brooklyn ImmunoTherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cinedigm$72.33M10.31-$9.35M-$0.05-79.80
Brooklyn ImmunoTherapeuticsN/AN/AN/A-$2.27-0.27

Cinedigm and Brooklyn ImmunoTherapeutics both received 0 outperform votes by MarketBeat users.

CompanyUnderperformOutperform
CinedigmOutperform Votes
No Votes
Underperform Votes
57
100.00%
Brooklyn ImmunoTherapeuticsOutperform Votes
No Votes
Underperform Votes
95
100.00%

Cinedigm has a beta of 2.05, suggesting that its stock price is 105% more volatile than the S&P 500. Comparatively, Brooklyn ImmunoTherapeutics has a beta of 4.61, suggesting that its stock price is 361% more volatile than the S&P 500.

Summary

Brooklyn ImmunoTherapeutics beats Cinedigm on 4 of the 7 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CIDM vs. The Competition

MetricCinedigmMotion Picture and Video Production IndustryInformation SectorNASDAQ Exchange
Market Cap$745.79M$500.93M$5.64B$8.90B
Dividend YieldN/AN/A3.69%4.07%
P/E Ratio-76.80N/A8.0313.46
Price / Sales10.316.935.9787.66
Price / CashN/AN/AN/A36.27
Price / BookN/AN/AN/A6.30
Net Income-$9.35MN/AN/A$225.93M

Cinedigm Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CIDM
Cinedigm
N/A$3.99
+3.9%
N/A+255.6%$745.79M$72.33M-76.80140
BTX
Brooklyn ImmunoTherapeutics
N/A$0.61
-12.8%
N/A-37.6%$36.16MN/A-0.27N/AGap Down
ALFIW
Alfi
N/A$0.00
flat
N/AN/A$0.00$200,684.000.0040
NLOK
NortonLifeLock
0.9854 of 5 stars
$29.44
+0.7%
N/A+41.5%$16.82B$2.82B20.59N/AAnalyst Forecast
News Coverage

Related Companies and Tools


This page (NASDAQ:CIDM) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners